Molecular Therapy · 2021 · 17 citations · 3 references
MedicineBiotechnologyPharmaceutical PolicyBioethicsGene TherapyMedical EthicsBiosafety In Gene TherapyBiotechnology EthicsClinical Trial AuthorizationClinical Trial EthicsGenetic EthicsSafety Of Gene TherapyAccessAccess To Trial TreatmentsBiopharmaceutical LicensingExpanded Access UseGene Therapy EthicsLabeling Of Gene TherapiesRelease Of Investigational Products
In the US, gene therapy companies, as with all biopharmaceutical companies, are not required by law or regulation to provide their investigational products to patients via non-trial preapproval (expanded) access. However, we believe that gene therapy companies, in particular, have a moral obligation to develop policies regarding such access, historically known as “compassionate use.” Gene therapies are predominantly intended for patients with serious or life-threatening rare diseases for which there are limited treatments;1 this should compel companies to develop product-specific non-trial preapproval access policies.
3
What compassionate use means for gene therapies
Carolyn Riley Chapman, Kenneth I. Moch, Andrew McFadyen et al. · Nature Biotechnology · 2019 · 23 citations